An open multicentre study of the treatment of florid schizophrenia with remoxipride

McCreadie, Robin G.; Morrison, Denis; Eccleston, D.; Gall, Ralph; Loudon, J. B.; Mitchell, M. J.

doi:10.1111/j.1600-0447.1985.tb02585.x

Cited by 39 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are not in line with theoretical consider ations regarding receptor binding of remoxipride [Ogren et al, 1983] and clinical findings concerning the absence of severe motor impairment [Laursen and Gerlach, 1986;McGreadie et al, 1985]. As our test results are not caused by different baseline levels, deterioration o f'subclinical' fine movements by the benzamide could be assumed, as well as the higher frequency and higher dos age of sedatives in the remoxipride group must be taken into account.…”

Section: Discussioncontrasting

confidence: 54%

Comparison of Sensorimotor and Cognitive Performance of Acute Schizophrenic Inpatients Treated with Remoxipride or Haloperidol

Classen

Laux²

1989

Neuropsychobiology

View full text Add to dashboard Cite

29 acute schizophrenic patients according to DSM III and ICD-9 underwent examination of performance regarding cognitive and sensorimotor tasks at the beginning and the end of a 28-day neuroleptic treatment with remoxipride or haloperidol in a double-blind design. Psychopathological symptoms were assessed by Brief Psychiatric Rating Scale and Clinical Global Impression, extrapyramidal side effects (ESE) were rated by Simpson-Angus scale. A significant treatment effect for acoustic reaction time tasks, naming of colored stripes and interference could be demonstrated, whereas tapping revealed a significant effect of duration of treatment. Interaction effects regarding time of faults in line tracing, visual sensorimotor reaction time task and interference factor (Stroop test) could be observed. ESE and impairment of performance occurred simultaneously and ESE vanished with clinical improvement. Performance deficits were more pronounced in patients assigned to remoxipride treatment. Possible differential effects on performance under neuroleptic drug treatment will be discussed.

show abstract

Section: Discussioncontrasting

confidence: 54%

Comparison of Sensorimotor and Cognitive Performance of Acute Schizophrenic Inpatients Treated with Remoxipride or Haloperidol

Classen

Laux²

1989

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…Indeed, early clinical trials showed that these drugs induced less extrapyramidal side effects than typical neuroleptics such as haloperidol (Guy et al, 1983;Chouinard and Annable, 1984;Lindstrom et al, 1985;McCreadie et al, 1985;Schwarcz et al, 1985;Patris et al, 1990;Lapierre et al, 1992;Gewirtz et al, 1994). However, receptor binding studies revealed that these atypical neuroleptics also have a significant affinity for a receptors (Largent et al, 1988).…”

Section: Introductionmentioning

confidence: 93%

BMY-14802 reversed the ? receptor agonist-induced neck dystonia in rats

Okumura

Ujike

Akiyama

et al. 1996

J. Neural Transmission

View full text Add to dashboard Cite

To clarify clinical roles of sigma receptor binding affinity of neuroleptics, neck dystonia induced by microinjection of sigma receptor ligands and neuroleptics into rat red nucleus was investigated. DTG and (+)-3-PPP, putative sigma receptor agonists, induced neck dystonia in dose-dependent and reversible manner. Haloperidol and perphenazine induced dystonia in the same way as sigma receptor agonists, whereas zotepine and (-)-sulpiride did not. The rank order of potency in induction of dystonia and sigma receptor affinity of these compounds showed positive correlation. Although BMY-14802 has a high affinity for sigma receptors, it never produced dystonia by itself. On the other hand, combined injection of BMY-14802 with DTG attenuated DTG-induced dystonia. Therefore, it is suggested that typical neuroleptics such as haloperidol act agonistic and atypical neuroleptics such as BMY-14802 act antagonistic at rubral sigma receptors in the induction of neck dystonia.

show abstract

“…69,70 Remoxipride and raclopride are two other recently described members of this class. They are also selective D2 receptor blockers with preferential action in mesolimbic areas 71 and their clinical efficacy has been evaluated in several studies [72][73][74][75] in which they showed an antipsychotic efficacy comparable to that of traditional neuroleptics, demonstrating that the selective dopaminergic approach has consistently produced compounds that are currently employed in the clinical treatment of schizophrenia.…”

Section: Dopamine Depression and Schizophreniamentioning

confidence: 99%

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Pani

Gessa

2002

Mol Psychiatry

View full text Add to dashboard Cite

In this paper the historical and scientific background that led to the use of substituted benzamides in two apparently unrelated clinical conditions namely dysthymic disorder and schizophrenia will be reviewed, in order to understand if a common mechanism of action may support this dual therapeutic indication. The dopaminergic antidepressant action of substituted benzamides such as sulpiride, has been proposed, since the late 1970s, by several authors and extensively explored in preclinical experiments by our group. In Italy the first marketing authorization obtained for the new substituted benzamide amisulpride, was with the sole indication of dysthymia and therefore a solid clinical experience exists in the use of substituted benzamides in mild forms of depression, with more than 1 000 000 patients being treated in the last 7 years. The proposed mechanism of action of substituted benzamides implies a selective modulation of the dopaminergic system in the mesocorticolimbic area, important for cognitive processing of internal and external cues, related to survival. The selective antagonism of dopamine D2-D3 receptors has been evoked to explain, in small to moderate doses (ie 50-100 mg day −1 ), the antidepressant effect and, in moderate to medium doses (100-400 mg day −1 ), the reported efficacy on negative symptoms of schizophrenia. Thus, substituted benzamides could represent the first class of atypical antipsychotics successfully employed for both depressive states and schizophrenia. Interestingly, recent evidence in the literature suggests that depressive episodes belonging to the bipolar spectrum are among 'alternative indications' of other atypical antipsychotics such as olanzapine and risperidone.

show abstract

An open multicentre study of the treatment of florid schizophrenia with remoxipride

Cited by 39 publications

References 8 publications

Comparison of Sensorimotor and Cognitive Performance of Acute Schizophrenic Inpatients Treated with Remoxipride or Haloperidol

Comparison of Sensorimotor and Cognitive Performance of Acute Schizophrenic Inpatients Treated with Remoxipride or Haloperidol

BMY-14802 reversed the ? receptor agonist-induced neck dystonia in rats

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Contact Info

Product

Resources

About